{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Kidney+%28Renal+Cell%29+Cancer&page=46",
    "query": {
      "condition": "Kidney (Renal Cell) Cancer",
      "page": 46
    },
    "page_size": 10
  },
  "pagination": {
    "page": 46,
    "page_size": 10,
    "total_count": 1535,
    "total_pages": 154,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Kidney+%28Renal+Cell%29+Cancer&page=47&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Kidney+%28Renal+Cell%29+Cancer&page=45&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-22T16:21:11.624Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02635672",
      "title": "Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neoplasms"
      ],
      "interventions": [
        {
          "name": "VIP152 (BAY 1251152)",
          "type": "DRUG"
        },
        {
          "name": "VIP152 (BAY 1251152) 30 mg",
          "type": "DRUG"
        },
        {
          "name": "Keytruda",
          "type": "DRUG"
        },
        {
          "name": "VIP152 (BAY 1251152) 15 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vincerx Pharma, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 110,
      "start_date": "2016-02-10",
      "completion_date": "2024-11-11",
      "has_results": false,
      "last_update_posted_date": "2024-11-15",
      "last_synced_at": "2026-10-22T16:21:11.624Z",
      "location_count": 13,
      "location_summary": "Springdale, Arkansas • Louisville, Kentucky • Silver Spring, Maryland + 10 more",
      "locations": [
        {
          "city": "Springdale",
          "state": "Arkansas"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Silver Spring",
          "state": "Maryland"
        },
        {
          "city": "Hackensack",
          "state": "New Jersey"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02635672"
    },
    {
      "nct_id": "NCT00931931",
      "title": "HSV1716 in Patients With Non-Central Nervous System (Non-CNS) Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Rhabdomyosarcoma",
        "Osteosarcoma",
        "Ewing Sarcoma",
        "Soft Tissue Sarcoma",
        "Neuroblastoma",
        "Wilms Tumor",
        "Malignant Peripheral Nerve Sheath Tumor",
        "Clival Chordoma",
        "Non-CNS Solid Tumors"
      ],
      "interventions": [
        {
          "name": "HSV1716",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Timothy Cripe",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "7 Years",
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "7 Years to 30 Years"
      },
      "enrollment_count": 18,
      "start_date": "2010-03",
      "completion_date": "2018-03-19",
      "has_results": false,
      "last_update_posted_date": "2018-03-21",
      "last_synced_at": "2026-10-22T16:21:11.624Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00931931"
    },
    {
      "nct_id": "NCT00474786",
      "title": "Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Renal Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Sorafenib",
          "type": "DRUG"
        },
        {
          "name": "temsirolimus (Torisel)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 512,
      "start_date": "2007-09",
      "completion_date": "2013-01",
      "has_results": true,
      "last_update_posted_date": "2013-11-21",
      "last_synced_at": "2026-10-22T16:21:11.624Z",
      "location_count": 26,
      "location_summary": "Duarte, California • La Jolla, California • Los Angeles, California + 19 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00474786"
    },
    {
      "nct_id": "NCT00262886",
      "title": "Donor Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Relapsed or Refractory Metastatic Kidney Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Kidney Cancer"
      ],
      "interventions": [
        {
          "name": "anti-thymocyte globulin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "graft-versus-tumor induction therapy",
          "type": "BIOLOGICAL"
        },
        {
          "name": "therapeutic allogeneic lymphocytes",
          "type": "BIOLOGICAL"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "fludarabine phosphate",
          "type": "DRUG"
        },
        {
          "name": "mycophenolate mofetil",
          "type": "DRUG"
        },
        {
          "name": "tacrolimus",
          "type": "DRUG"
        },
        {
          "name": "allogeneic bone marrow transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "peripheral blood stem cell transplantation",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "University of Rochester",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 35,
      "start_date": "2001-08",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-06-06",
      "last_synced_at": "2026-10-22T16:21:11.624Z",
      "location_count": 1,
      "location_summary": "Rochester, New York",
      "locations": [
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00262886"
    },
    {
      "nct_id": "NCT00401583",
      "title": "A Study To Test The Effect Of GW786034 (Pazopanib) On P450 Enzymes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Carcinoma, Renal Cell"
      ],
      "interventions": [
        {
          "name": "GW786034 (pazopanib)",
          "type": "DRUG"
        },
        {
          "name": "Probe drugs",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2006-07-28",
      "completion_date": "2008-02-20",
      "has_results": false,
      "last_update_posted_date": "2017-11-13",
      "last_synced_at": "2026-10-22T16:21:11.624Z",
      "location_count": 1,
      "location_summary": "Lebanon, New Hampshire",
      "locations": [
        {
          "city": "Lebanon",
          "state": "New Hampshire"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00401583"
    },
    {
      "nct_id": "NCT00423254",
      "title": "Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Ovarian",
        "Melanoma",
        "Renal",
        "Prostate",
        "Colorectal",
        "Endometrial Carcinoma",
        "Cervical Carcinoma",
        "Testicular Cancer",
        "Thyroid Cancer",
        "Small Cell Lung Carcinoma",
        "Mesothelioma",
        "Breast Carcinoma",
        "Esophageal Carcinoma",
        "Gastric Cancer",
        "Pancreatic Carcinoma",
        "Neuroendocrine Cancer",
        "Liver Cancer",
        "Gallbladder Cancer",
        "Biliary Tract Cancer",
        "Anal Carcinoma",
        "Bone Sarcomas",
        "Soft Tissue Sarcomas",
        "Carcinoma of Unknown Origin, Primary"
      ],
      "interventions": [
        {
          "name": "PSMA/PRAME",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Mannkind Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2007-02",
      "completion_date": "2009-11",
      "has_results": false,
      "last_update_posted_date": "2010-08-03",
      "last_synced_at": "2026-10-22T16:21:11.624Z",
      "location_count": 5,
      "location_summary": "Tuscon, Arizona • Washington D.C., District of Columbia • Tampa, Florida + 2 more",
      "locations": [
        {
          "city": "Tuscon",
          "state": "Arizona"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Sparks",
          "state": "Nevada"
        },
        {
          "city": "Lebanon",
          "state": "New Hampshire"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00423254"
    },
    {
      "nct_id": "NCT05987241",
      "title": "Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Muscle Invasive Bladder Urothelial Carcinoma",
        "Muscle Invasive Renal Pelvis Urothelial Carcinoma",
        "Muscle Invasive Ureter Urothelial Carcinoma",
        "Muscle Invasive Urethral Urothelial Carcinoma",
        "Stage II Bladder Urothelial Carcinoma AJCC v6 and v7",
        "Stage III Bladder Urothelial Carcinoma AJCC v6 and v7",
        "Stage IV Bladder Urothelial Carcinoma AJCC v7"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "cfDNA or ctDNA Measurement",
          "type": "OTHER"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Cystoscopy",
          "type": "PROCEDURE"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        },
        {
          "name": "Relatlimab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 992,
      "start_date": "2024-02-02",
      "completion_date": "2030-09-02",
      "has_results": false,
      "last_update_posted_date": "2026-10-22",
      "last_synced_at": "2026-10-22T16:21:11.624Z",
      "location_count": 492,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 372 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05987241"
    },
    {
      "nct_id": "NCT00303732",
      "title": "Vatalanib and Everolimus in Treating Patients With Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Kidney Cancer",
        "Unspecified Adult Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "RAD001 (everolimus)",
          "type": "DRUG"
        },
        {
          "name": "PTK787 (vatalanib)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Daniel George, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 37,
      "start_date": "2004-12",
      "completion_date": "2012-08",
      "has_results": false,
      "last_update_posted_date": "2016-03-03",
      "last_synced_at": "2026-10-22T16:21:11.624Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00303732"
    },
    {
      "nct_id": "NCT00505310",
      "title": "Biobehavioral Effects of Emotional Expression in Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Kidney Cancer"
      ],
      "interventions": [
        {
          "name": "Writing",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Questionnaire",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 705,
      "start_date": "2002-08-21",
      "completion_date": "2022-08-10",
      "has_results": false,
      "last_update_posted_date": "2022-08-30",
      "last_synced_at": "2026-10-22T16:21:11.624Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00505310"
    },
    {
      "nct_id": "NCT05873686",
      "title": "A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumor",
        "NSCLC (Non-small Cell Lung Cancer)",
        "Renal Cancer",
        "Mesothelioma",
        "Non-Small Cell Squamous Lung Cancer",
        "Non-small Cell Lung Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "NXP900",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Nuvectis Pharma, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 140,
      "start_date": "2023-10-26",
      "completion_date": "2027-07",
      "has_results": false,
      "last_update_posted_date": "2026-09-30",
      "last_synced_at": "2026-10-22T16:21:11.624Z",
      "location_count": 13,
      "location_summary": "Phoenix, Arizona • La Jolla, California • Denver, Colorado + 9 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05873686"
    }
  ]
}